Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$43.85 USD
-0.43 (-0.97%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $43.84 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum D VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 5/2/24 |
---|---|
Current Quarter | -1.72 |
EPS Last Quarter | -1.52 |
Last EPS Surprise | 7.88% |
ABR | 1.24 |
Earnings ESP
|
0.00% |
---|---|
Current Year | -6.36 |
Next Year | -5.12 |
EPS (TTM) | -8.33 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | 114.39M | 125.27M | 514.22M | 611.95M |
# of Estimates | 9 | 9 | 9 | 9 |
High Estimate | 123.09M | 130.00M | 530.01M | 709.29M |
Low Estimate | 98.80M | 120.38M | 500.11M | 541.73M |
Year ago Sales | 100.50M | 108.31M | 434.25M | 514.22M |
Year over Year Growth Est. | 13.82% | 15.66% | 18.42% | 19.01% |
Earnings Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -1.72 | -1.56 | -6.36 | -5.12 |
# of Estimates | 11 | 9 | 12 | 11 |
Most Recent Consensus | -1.60 | -1.51 | -6.65 | -3.87 |
High Estimate | -1.40 | -1.36 | -5.23 | -2.33 |
Low Estimate | -2.02 | -1.74 | -8.32 | -7.05 |
Year ago EPS | -2.33 | -2.25 | -8.25 | -6.36 |
Year over Year Growth Est. | 26.18% | 30.67% | 22.91% | 19.47% |
Agreement - Estimate Revisions
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 0 | 0 | 0 | 0 |
Up Last 60 Days | 1 | 1 | 2 | 1 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 0 | 0 | 1 | 1 |
Down Last 60 Days | 0 | 0 | 1 | 1 |
Magnitude - Consensus Estimate Trend
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -1.72 | -1.56 | -6.36 | -5.12 |
7 Days Ago | -1.72 | -1.56 | -6.36 | -5.12 |
30 Days Ago | -1.72 | -1.56 | -6.34 | -5.10 |
60 Days Ago | -1.73 | -1.57 | -6.41 | -5.05 |
90 Days Ago | -1.66 | -1.54 | -6.39 | -4.79 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -1.72 | -1.56 | -8.32 | -7.05 |
Zacks Consensus Estimate | -1.72 | -1.56 | -6.36 | -5.12 |
Earnings ESP | 0.00% | 0.00% | -30.83% | -37.67% |
Surprise - Reported Earnings History
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Quarter Ending (3/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -1.52 | -2.23 | -2.25 | -2.33 | NA |
Estimate | -1.65 | -2.08 | -2.11 | -1.97 | NA |
Difference | 0.13 | -0.15 | -0.14 | -0.36 | -0.13 |
Surprise | 7.88% | -7.21% | -6.64% | -18.27% | -6.06% |
Quarterly Estimates By Analyst
Zacks Premium Subscription Required Learn more
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more